Abstract InChina, COVID-19 epidemic is currently showing a sporadic state, and the task of epidemic prevention is still arduous. Brachytherapy (BT) plays a critical role in the treatment of cancer. For some cancer receiving radiotherapy, use of BT can not be replaced or excessively delayed. Nevertheless, the recommendations or guidelines regarding the application of BT during COVID-19 epidemic have been rarely reported. In this article, a few recommendations on the application of BT during COVID-19 epidemic were retrieved and the work experience of Department of Radiation Oncology, China-Japan Union Hospital of Jilin University in the early epidemic period was summarized, aiming to provide relevant reference for the use of high-dose-rate BT for malignant tumor patients during COVID-19 epidemic.
Fund:National Natural Science Foundation of China (81703034);Project of Science and Technology Department of Jilin Province (20190303151SF);Horizontal Project of Jilin university (2019YX435)
Zhang Ning,Zhao Hongfu,Cheng Guanghui et al. Recommendations on high-dose-rate rachytherapy for malignant tumors during COVID-19 epidemic[J]. Chinese Journal of Radiation Oncology, 2020, 29(11): 932-936.
Zhang Ning,Zhao Hongfu,Cheng Guanghui et al. Recommendations on high-dose-rate rachytherapy for malignant tumors during COVID-19 epidemic[J]. Chinese Journal of Radiation Oncology, 2020, 29(11): 932-936.
[1] Aghili M, Ghalehtaki R, Mousavi Darzikolaee N, et al. Radiotherapy and COVID-19:Practical recommendations from iran[J]. Radiother Oncol, 2020, 149(1):70-71. DOI:10.1016/j.radonc.2020.04.051. [2] Sriwijitalai W, Wiwanitkit V. COVID-19, radiotherapy and cancer[J]. Radiother Oncol, 2020, 149(1):48. DOI:10.1016/j.radonc.2020.04.023. [3] Guckenberger M, Belka C, Bezjak A, et al. Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic:An ESTRO-ASTRO consensus statement[J]. Radiother Oncol, 2020, 146(2):223-229. DOI:10.1016/j.radonc.2020.04.001. [4] Braunstein LZ, Gillespie EF, Hong L, et al. Breast radiation therapy under COVID-19 pandemic resource constraints-approaches to defer or shorten treatment from a comprehensive cancer center in the United States[J]. Adv Radiat Oncol, 2020, 5(4):582-588. DOI:10.1016/j.adro.2020.03.013. [5] Mohindra P, Beriwal S, Kamrava M. Proposed brachytherapy recommendations (practical implementation, indications, and dose fractionation) during COVID-19 pandemic[J]. Brachytherapy, 2020, 19(4):390-400. DOI:10.1016/j.brachy.2020.04.009. [6] Wu N, Chen Q, Zhao Z, et al. Interstitial brachytherapy technique for chest wall refractory recurrence of breast cancer[J]. J Contemp Brachytherapy, 2015, 7(4):290-294. DOI:10.5114/jcb.2015.53868. [7] Karlsson P, Cole BF, Colleoni M, et al. Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy[J]. Int J Radiat Oncol Biol Phys, 2011, 80(2):398-402. DOI:10.1016/j.ijrobp.2010.02.042. [8] Olivotto IA, Lesperance ml, Truong PT, et al. Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy[J]. J Clin Oncol, 2009, 27(1):16-23. DOI:10.1200/JCO.2008.18.1891. [9] Shurell E, Olcese C, Patil S, et al. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ[J]. Cancer, 2018, 124(1):46-54. DOI:10.1002/cncr.30972. [10] Aghili M, Lashkari M, Babaei M, et al. Accelerated partial breast irradiation:a new strategy for early-stage breast cancer[J]. Arch Breast Cancer, 2019,63(1):102-112. DOI:10.32768/abc.201963102-112. [11] Barthwal M, Pareek V, Mallick S, et al. Brachytherapy practice during the COVID-19 pandemic:a review on the practice changes[J]. J Contempor Brachyther, 2020, 12(4):393-396. DOI:10.5114/jcb.2020.97643. [12] Girinsky T, Rey A, Roche B, et al. Overall treatment time in advanced cervical carcinomas:a critical parameter in treatment outcome[J]. Int J Radiat Oncol Biol Phys, 1993, 27(5):1051-1056. DOI:10.1016/0360-3016(93)90522-W. [13] Beriwal S, Kannan N, Kim H, et al. Three-dimensional high dose rate intracavitary image-guided brachytherapy for the treatment of cervical cancer using a hybrid magnetic resonance imaging/computed tomography approach:feasibility and early results[J]. Clin Oncol (R Coll Radiol), 2011, 23(10):685-690. DOI:10.1016/j.clon.2011.08.007. [14] Viswanathan AN, Beriwal S, De Los Santos JF, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part Ⅱ:high-dose-rate brachytherapy[J]. Brachytherapy, 2012, 11(1):47-52. DOI:10.1016/j.brachy.2011.07.002. [15] Albuquerque K, Hrycushko BA, Harkenrider MM, et al. Compendium of fractionation choices for gynecologic HDR brachytherapy-An American Brachytherapy Society Task Group Report[J]. Brachytherapy, 2019, 18(4):429-436. DOI:10.1016/j.brachy.2019.02.008. [16] Hendry J, Jones GW, Mahantshetty UM, et al. Radiobiological analysis of outcomes using external beam radiotherapy plus high dose-rate brachytherapy (4×7 Gy or 2×9 Gy) for cervical cancer in a multi-institution trial[J]. Int J Radiat Oncol Biol Phys, 2017, 99(5):1313-1314. DOI:10.1016/j.ijrobp.2017.09.009. [17] Tanderup K, Fokdal LU, Sturdza A, et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer[J]. Radiother Oncol, 2016, 120(3):441-446. DOI:10.1016/j.radonc.2016.05.014. [18] Niazi TM, Souhami L, Portelance L, et al. Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage Ⅰ-Ⅱ endometrial carcinoma[J]. Int J Radiat Oncol Biol Phys, 2005, 63(4):1108-1113. DOI:10.1016/j.ijrobp.2005.04.036. [19] Schwarz JK, Beriwal S, Esthappan J, et al. Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer[J]. Brachytherapy, 2015, 14(5):587-599. DOI:10.1016/j.brachy.2015.06.002. [20] Cattaneo R, 2nd, Hanna RK, Jacobsen G, et al. Interval between hysterectomy and start of radiation treatment is predictive of recurrence in patients with endometrial carcinoma[J]. Int J Radiat Oncol Biol Phys, 2014, 88(4):866-871. DOI:10.1016/j.ijrobp.2013.11.247. [21] Fabrini MG, Gadducci A, Perrone F, et al. Relationship between interval from surgery to radiotherapy and local recurrence rate in patients with endometrioid-type endometrial cancer:a retrospective mono-institutional Italian study[J]. Anticancer Res, 2012, 32(1):169-173. [22] Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2):an open-label, non-inferiority, randomised trial[J]. Lancet, 2010, 375(9717):816-823. DOI:10.1016/S0140-6736(09)62163-2. [23] Miriyala R, Mahantshetty U. Brachytherapy in cervical cancer radiotherapy during COVID-19 pandemic crisis:problems and prospects[J]. J Contempor Brachyther, 2020, 12(3):290-293. DOI:10.5114/jcb.2020.96873. [24] Merrick GS, Wallner KE, Galbreath RW, et al. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials[J]. Brachytherapy, 2015, 14(5):677-685. DOI:10.1016/j.brachy.2015.05.001. [25] Martell K, Mendez LC, Chung HT, et al. Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer:Analysis of over 500 patients[J]. Radiother Oncol, 2019, 141(2):149-155. DOI:10.1016/j.radonc.2019.08.017. [26] Shahid N, Loblaw A, Chung HT, et al. Long-term toxicity and health-related quality of life after single-fraction high dose rate brachytherapy boost and hypofractionated external beam radiotherapy for intermediate-risk prostate cancer[J]. Clin Oncol (R Coll Radiol), 2017, 29(7):412-420. DOI:10.1016/j.clon.2017.01.042. [27] Yamada Y, Kollmeier MA, Pei X, et al. A Phase Ⅱ study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy[J]. Brachytherapy, 2014, 13(2):111-116. DOI:10.1016/j.brachy.2013.11.005. [28] Chen CP, Weinberg V, Shinohara K, et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy:5-year outcomes[J]. Int J Radiat Oncol Biol Phys, 2013, 86(2):324-329. DOI:10.1016/j.ijrobp.2013.01.027. [29] Kalaghchi B, Esmati E, Ghalehtaki R, et al. High-dose-rate brachytherapy in treatment of non-melanoma skin cancer of head and neck region:preliminary results of a prospective single institution study[J]. J Contemp Brachytherapy, 2018, 10(2):115-122. DOI:10.5114/jcb.2018.75596.
2020, Vol. 29 
